In localized intermediate‐grade prostate cancer, current clinically established prognostic markers, such as PSA, lack sensitivity and specificity in distinguishing aggressive from indolent disease; toward this direction, the identification of novel prognostic methylation biomarkers for prostate cancer is highly important [48]. Here, PSAT1 is linked to prostate carcinoma.